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Objectives This study evaluated differences in outcome among women and men enrolled in the BARI 2D (Bypass Angio-
plasty Revascularization Investigation 2 Diabetes) trial.
Background Women and men with coronary artery disease have different clinical presentations and outcomes that might be
due to differences in management.
Methods We compared baseline variables, study interventions, and outcomes between women and men enrolled in the
BARI 2D trial and randomized to aggressive medical therapy alone or aggressive medical therapy with prompt
revascularization.
Results At enrollment, women were more likely than men to have angina (67% vs. 58%, p  0.01) despite less disease
on angiography (Myocardial Jeopardy Index 41  24 vs. 46  24, p  0.01; number of significant lesions 2.3 
1.7 vs. 2.8  1.8, p  0.01). Over 5 years, no sex differences were observed in BARI 2D study outcomes after
adjustment for difference in baseline variables (death/myocardial infarction/cerebrovascular accident: hazard
ratio: 1.11, 99% confidence interval [CI]: 0.85 to 1.44). However, women reported more angina than men (ad-
justed odds ratio: 1.51, 99% CI: 1.21 to 1.89, p  0.0001) and had lower scores for the Duke Activity Status
Index (adjusted beta coefficient: 1.58, 99% CI: 2.84 to 0.32, p  0.01).
Conclusions There were no sex differences in death, myocardial infarction, or cerebrovascular accident among patients enrolled in
the BARI 2D trial. However, compared with men, women had more symptoms and less anatomic disease at baseline,
with persistence of higher angina rates and lower DASI scores after 5 years of medical therapy with or without
prompt revascularization. (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes [BARI 2D];
NCT00006305) (J Am Coll Cardiol 2013;61:1767–76) © 2013 by the American College of Cardiology Foundation
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Outcomes in Women and Men Enrolled in the BARI 2D Trial April 30, 2013:1767–76Previous studies have reported dif-
ferences in presenting clinical char-
acteristics (1–16) and outcome (2–9)
in women and men with coronary
artery disease (CAD). Women with
stable or unstable angina have been
shown to have less extensive disease
then men on coronary angiography
(3,4,6,8,11,16) and are less aggres-
sively treated than their male coun-
terparts (3,5–7,10,11,17,18). These
differences in clinical presentation
and treatment will likely confound
patient outcomes and therefore
make a comparison of outcomes by
sex more difficult. Some studies have
shown that after adjustment for clin-
ical and angiographic variables and
differences in therapy provided,
women and men had similar out-
comes (7,8,13–15). Other studies
report more restenosis or refractory
ischemia (11,12) and worse overall
outcomes in women compared with
men (2–6,9). The BARI 2D (By-
pass Angioplasty Revascularization
Investigation 2 Diabetes) trial data
provide an opportunity to examine sex differences in outcome in a
controlled population of patients with type 2 diabetes (DM) and
CAD amenable to revascularization, who are all treated with
similar protocol-mandated lifestyle and pharmaco-therapeutic
management strategies.
Methods
The BARI 2D trial was an international multicenter ran-
domized clinical trial that evaluated the optimal treatment
for patients with DM and documented CAD. A detailed
description of the study design and patient population has
been published previously (19–21). Between January 1,
2001, and March 31, 2005, a total of 2,368 participants
were enrolled from 49 clinical sites in the United States,
Canada, Brazil, Mexico, Czech Republic, and Austria.
Enrollment criteria included a history of DM and angio-
graphically documented CAD (defined as 50% stenosis of
a major epicardial coronary artery and an abnormal stress
test or 70% stenosis of a major epicardial artery with
typical angina), involving at least 1 coronary vessel that was
DC Department of Health, AstraZeneca, American College of Cardiology DM &
CVD CME program, and Quintiles/GE Centricity/Sanofi DIABETES FOR-
WARD. Ms. Mighton has received compensation for training healthcare profession-
als and patients for Abbot Diabetes Care. All other authors have reported that they
have no relationships relevant to the contents of this paper to disclose.
Abbreviations
and Acronyms
CABG  coronary artery
bypass surgery
CAD  coronary artery
disease
CHF  congestive heart
failure
CVA  cerebrovascular
accident
DASI  Duke Activity
Status Index
DM  type 2 diabetes
mellitus
HbA1c  glycosylated
hemoglobin
LDL  low-density
lipoprotein
MI  myocardial infarction
MJI  Myocardial Jeopardy
Index
OR  odds ratio
PCI  percutaneous
coronary intervention
QOL  quality of lifeManuscript received November 2, 2012; revised manuscript received December 17,
2012, accepted January 8, 2013.
fsuitable for treatment with either aggressive medical therapy
or elective revascularization with percutaneous coronary
intervention (PCI) or coronary artery bypass surgery
(CABG). Patients were excluded if they had unstable
symptoms necessitating revascularization, severe left main
disease (50% stenosis), PCI, or CABG in the preceding
12 months or a history of chronic kidney disease with a
serum creatinine above 2.0 mg/dl (176.8 mol/l). Physi-
ians were queried before randomization with regard to the
ecommended method of revascularization, and patients
ntered into either the PCI or CABG stratum. Patients
ere then randomized in a 2  2 factorial design to a
trategy of prompt revascularization plus intensive medical
herapy versus initial intensive medical therapy alone with
linically indicated revascularization for treatment of CAD.
ubjects were randomly assigned to an insulin-providing
r an insulin-sensitizing strategy for glycemic control.
he primary endpoint of the BARI 2D trial was the rate
f death from any cause. The principal secondary end-
oint was a composite of death, myocardial infarction
MI), or stroke (cerebrovascular accident [CVA]) at 5
ears of follow-up.
Baseline Demographic Data andClinical Characterist s in Women and MenTable 1 Bas l ne Demographic Data a dClinical Characteristics in Women and Men
Characteristics
Women
(n  702)
Men
(n  1,666) p Value
Age at entry, yrs 62.9 9.3 62.2 8.7 0.11
Race, ethnicity 0.01
White, non-Hispanic 55.8% 70.1%
Black, non-Hispanic 27.6% 12.2%
Hispanic 12.7% 12.5%
Asian and others 3.8% 5.2%
History of MI 28.0% 33.8% 0.01
History of hypertension 87.1% 80.6% 0.01
Prior revascularization 22.4% 24.1% 0.37
Diabetes duration, yrs 12.2 9.6 9.7 8.1 0.01
History of CHF 7.8% 6.2% 0.14
BMI (kg/m2) 32.8 6.9 31.3 5.5 0.01
Neuropathy: clinical MNSI 2 45.7% 52.2% 0.01
Intermittent claudication 20.4% 16.4% 0.02
History of cigarette smoking 48.4% 74.7% 0.01
Current smoker 10.3% 13.4%
Angina 66.5% 58.2% 0.01
Stable CCS I–II 63.7% 73.1% 0.01
Stable CCS III–IV 17.8% 12.5%
Unstable 18.5% 14.4%
Angina equivalents 72.6% 60.1% 0.01
DASI 14.1 10.7 21.0 14.0 0.01
Self-Rated Health 60.8 20.7 65.1 18.5 0.01
LDL 100 mg/dl 50.8% 63.3% 0.01
Triglycerides 150 mg/dl 52.1% 49.9% 0.34
Blood pressure 130/80 mm Hg 44.8% 48.7% 0.08
HbA1c 7.0% 32.3% 42.7% 0.01
Values are mean  SD, %, or n.
BMI  body mass index; CCS  Canadian Cardiovascular Society; CHF  congestive heartailure; DASI  Duke Activity Status Index; HbA1c  glycosylated hemoglobin; LDL  low-density
lipoprotein; MI  myocardial infarction; MSNI  Michigan Neuropathy Screening Instrument.
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April 30, 2013:1767–76 Outcomes in Women and Men Enrolled in the BARI 2D TrialOther secondary outcomes included congestive heart
failure (CHF), the first subsequent revascularization, angina
status, and quality of life (QOL). The subsequent revascu-
larization was defined as the first clinically indicated revas-
cularization among patients randomized to the aggressive
medical therapy strategy or the second revascularization
among patients randomized to the revascularization strat-
egy. Angina status was reported at baseline, each month in
the first 6 months of follow-up visits, and quarterly after-
ward. The QOL was assessed at baseline and at each annual
follow-up visit. Self-administered questionnaires, including
the Duke Activity Status Index (DASI) (22) and Self-Rated
Health were used to assess the activity status and perceived
health of a patient. The DASI is a 12-item index question-
naire assessing the ability of a patient to perform various
activities without difficulty. Examples of activities assessed
with DASI include walking a block on flat ground, climbing
stairs, or doing housework. Each item is “weighted” such
that the value for each question correlates with the meta-
bolic cost of the activity described. The DASI scores range
from 0 (worst—essentially unable to perform any activities
independently) to 58.2 (best). Self-Rated Health is a single
question administered to patients: “In general, would you
say your health is excellent, very good, good, fair, or poor?”
The responses are given numerical grades ranging from 0
(worst) to 100 (best).
In the current study, all comparisons were made between
women and men. A descriptive analysis was performed for
all baseline characteristics. Chi-square tests were performed
to test general associations between sex and categorical
characteristics. Two-sample t tests were conducted for the
omparisons of means of continuous variables. The cumu-
ative rate of event-type outcomes—including death; the
omposite of death, MI, or CVA; CHF; and the first
Baseline Angiographic Data in Women and MenTable 2 Baseline Angiographic Data in Women and Men
Angiographic Data
Women
(n  702)
Men
(n  1,666)
Number of significant (50%)
lesions
2.3 1.7 2.8 1.8 0.01
Number of diseased region 0.01
0–1 39.5% 30.9%
2 36.5% 35.6%
3 24.0% 33.5%
MJI 41.0 23.7 45.9 24.2 0.01
Category of MJI 0.01
0%–20% 22.3% 16.8%
21%–50% 45.5% 42.2%
51%–100% 32.2% 41.1%
Total occlusion 31.1% 45.3% 0.01
Significant proximal LAD (50%) 11.0% 14.2% 0.04
LVEF 50% 12.0% 19.7% 0.01
LVEF, % 58.8 10.4 56.5 11.1 0.01
Values are mean  SD or %.
LAD left anterior descending artery; LVEF left ventricular ejection fraction; MJIMyocardial
Jeopardy Index.ubsequent revascularization—were compared with Kaplan- PMeier estimators. The comparisons were further assessed by
multivariable Cox regression models, adjusting for random-
ization strategy of CAD (medical therapy vs. revasculariza-
tion) and glycemic control (insulin sensitizing vs. insulin
providing); intended revascularization (PCI or CABG stra-
tum); and relevant baseline characteristics including age,
race, enrollment site, history of MI, hypertension, angina
status, duration of DM, smoking history, number of left
ventricular diseased regions, and abnormal left ventricular
ejection fraction (50%). Other repeated measured out-
comes included angina status and QOL over 5 years of
follow-up, where the follow-up year was coded as a cate-
gorical variable. The annual prevalence of angina was
compared with chi-square test. Furthermore, a longitudinal
logistic model with an approach of generalized estimating
equations was constructed to estimate the overall odds ratio
(OR) comparing women with men, adjusted for follow-up
year, randomization strategies, intended revascularization
strata, baseline angina status, and other baseline character-
istics as listed in the preceding text. A similar approach was
used to estimate the OR for achieving guideline recom-
mended targets of low-density lipoprotein (LDL) 100
g/dl, glycosylated hemoglobin (HbA1c) 7% and blood
ressure 130/80 mm Hg over 5 years of follow-up. The
nnual score of DASI and Self-Rated Health were com-
Characteristics of RevascularizationProcedure in Subjects Randomizedto R vascularization in Women and Men
Table 3
Ch racteri tics of R vascularization
Procedures in Subjects Randomized
to Revascularization in Women and Men
Initial PCI Procedures
Women
(n  244)
Men
(n  521) p Value
Residual MJI 0.46
0% 44% 38%
1%–20% 27% 27%
21%–50% 24% 28%
51%–100% 5% 6%
Number of intended lesions 1.52 0.87 1.53 0.79 0.89
Number of successful lesions 1.46 0.83 1.45 0.79 0.90
Presence of lesion
complications (%)
5.7% 5.6% 0.92
Initial CABG Procedures
Women
(n  87)
Men
(n  260) p Value
Residual MJI 0.59
0% 33% 30%
1%–20% 30% 36%
21%–50% 36% 32%
51%–100% 1% 3%
Number of conduits grafted 2.67 0.9 2.92 0.9 0.03
Number of grafts 2.55 0.9 2.88 0.9 0.01
Number of arterial conduits 1.09 0.5 1.25 0.6 0.04
Intended lesions not grafted (%) 17% 13% 0.33
Values are % or mean  SD.
CABG  Coronary Artery Bypass Graft Surgery; MJI  Myocardial Jeopardy Index; PCI 
ercutaneous Coronary Intervention.
m
a
l
a
t
u
c
l
W
t
c
w
h
l
r
(
b
c
j
m
t
a
m
M
t
g
e
t
C
u
t
T
p
s
t
b
w
s
s.
istered
1770 Tamis-Holland et al. JACC Vol. 61, No. 17, 2013
Outcomes in Women and Men Enrolled in the BARI 2D Trial April 30, 2013:1767–76pared with t test. Longitudinal linear mixed models were
built to compare the follow-up health status scores by sex
with adjustment for time, randomization strategies, in-
tended revascularization strata, corresponding baseline
health status scores, and other baseline characteristics. The
interactions between sex and follow-up year and between
sex and randomization strategies were tested in each model
and dropped if not statistically significant. For the correc-
tion of multiple comparisons, the statistical significance
level was set at 0.01. Analyses were performed by SAS
(version 9.1.3, SAS, Cary, North Carolina). Figures were
plotted by R software (R Development Core Team).
Results
Baseline demographic and clinical variables are depicted in
Table 1. Among the 2,368 patients, 702 (29.6%) were
women. A larger proportion of women were black. Com-
pared with men, women reported longer durations of
diabetes, had a higher prevalence of hypertension, and were
less likely to have had a prior MI or to have ever smoked
cigarettes. The mean body mass index was higher in women
than men, and fewer women than men had an LDL 100
g/dl (2.6 mmol/l) and a HbA1c 7.0%. A larger percent-
ge of women than men reported angina or angina equiva-
ents. Women were more likely than men to have unstable
ngina in the 6 weeks preceding enrollment. Among pa-
ients with stable symptoms, more women than men had an
nfavorable Canadian Cardiovascular Society functional
lass (class 3 and 4). Women had lower DASI scores and
ower scores for Self-Rated Health.
Table 2 depicts the angiographic data stratified by sex.
Medication and Lifestyle Management at Baseline and in Follow-UpTable 4 Medication and Lifestyle Management at Baseline and
Baseline
Women
(n  702)
Men
(n  1,666) p Value
Medication
Beta-blocker 75% 72% 0.22
Calcium channel blocker 34% 30% 0.09
ACE or ARB 76% 78% 0.37
Nonsublingual nitrate 35% 30% 0.01
Diuretic 50% 34% 0.01
Any antiplatelet 88% 91% 0.07
Statin 73% 76% 0.14
Lifestyle changes
Exercise prescription* —
Dietary counseling with RD 47% 51% 0.08
Current smoking 10% 14% 0.02
Sample size of current smoker
at annual visits
—
Smoking cessation† —
Values are %. *The receipt of an exercise prescription from the cardiologist was not routinely doc
data for years 1 and 2. †Smoking cessation counseling was only implemented in current smoker
ACE  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor blocker; RD  regomen had less severe CAD with fewer significant lesions phan men, fewer total occlusions, and a lower mean Myo-
ardial Jeopardy Index (MJI). A smaller proportion of
omen had multiple diseased regions. Moreover, women
ad better left ventricular function and a lower prevalence of
eft ventricular dysfunction than men. Physicians more often
ecommended a PCI procedure for women than for men
74% vs. 65%, p  0.01). However, after adjustment for
aseline variables and extent of disease, the choice of PCI
ompared with CABG was not significantly different (ad-
usted OR for PCI vs. CABG in women compared with
en: 1.22, 99% CI: 0.88 to 1.70, p  0.12).
Table 3 depicts the procedural characteristics by sex for
he 765 patients assigned to initial PCI and 347 patients
ssigned to initial CABG. Procedural results for women and
en undergoing PCI were similar, with a similar residual
JI score and a similar number of intended and successfully
reated lesions. Women undergoing CABG received fewer
rafts than men. After adjusting for baseline variables and
xtent of disease, there was a borderline significant difference in
he number of grafts implanted in women and men during
ABG surgery (beta coefficient  0.29, p  0.013). Resid-
al MJI after CABG was similar in women and men.
Medications prescribed to patients and lifestyle changes
hat were advised by the healthcare team are depicted in
able 4. Overall, there were no sex differences in the
ercentage of patients treated with antiplatelet therapies,
tatins, angiotensin-converting enzyme inhibitors or angio-
ensin receptor blockers, beta-blockers, or calcium channel
lockers. However, a larger proportion of women than men
ere treated with non-sublingual nitrates and diuretics. A
imilar percentage of women and men was given exercise
omen and Menollow-Up in Women and Men
Follow-Up Year
1-Yr 2-Yr
en
632)
Men
(n  1,517) p Value
Women
(n  606)
Men
(n  1,441) p Value
% 86% 0.56 87% 85% 0.16
% 37% 0.16 37% 38% 0.90
% 89% 0.10 92% 90% 0.13
% 23% 0.09 26% 19% 0.01
% 48% 0.01 72% 54% 0.01
% 93% 0.36 94% 96% 0.14
% 94% 0.21 93% 94% 0.39
— —
% 56% 0.95 55% 53% 0.41
% 11% 0.02 8% 10% 0.07
47) (n  165) (n  45) (n  146)
% 74% 0.61 80% 76% 0.58
d on the case report form until November 2004. Therefore, there were large numbers of missing
dietitian.in Win F
Wom
(n 
87
40
92
27
68
92
93
56
8
(n 
70
umenterescriptions, received dietary counseling with a registered
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April 30, 2013:1767–76 Outcomes in Women and Men Enrolled in the BARI 2D Trialdietitian, and was administered treatments for smoking
cessation if they continued to smoke. Women were less
likely than men to achieve guideline-recommended target
goal for LDL 100 mg/dl over the 5 years of follow-up
(adjusted OR for achieving an LDL goal of 100 mg/dl in
women vs. men: 0.62, 99% CI: 0.50 to 0.77, p  0.0001).
The adjusted odds for achieving an HbA1c 7% or a blood
ressure130/80 mm Hg over 5 years of follow-up was not
ignificantly different by sex (adjusted OR for achieving an
bA1c goal of 7% in women vs. men: 0.95, 99% CI: 0.76
o 1.19, p  0.53; adjusted OR for achieving a blood
ressure 130/80 mm Hg in women vs. men: 0.95, 99%
I: 0.79 to 1.14, p  0.46).
The 5-year Kaplan-Meier event rates for the primary
ndpoints and the principal composite secondary endpoints
s well as other clinical outcomes in women and men are
epicted in Table 5 and Figure 1. Over 5 years, no sex
ifferences were observed in BARI 2D primary study
ContinuedTable 4 Continued
Follo
3-Yr
Women
(n  569)
Men
(n  1,392) p Value
Women
(n  498) (
90% 86% 0.01 88%
38% 38% 0.99 42%
92% 91% 0.37 92%
29% 18% 0.01 28%
75% 56% 0.01 77%
96% 96% 0.63 96%
95% 96% 0.43 95%
71% 74% 0.13 71%
54% 51% 0.28 52%
7% 10% 0.05 7%
(n  40) (n  130) (n  35)
98% 81% 0.01 89%
Clinical Outcomes in Women and MenTable 5 Clinical Outcomes in Women and M
Outcomes
5-Yr Cumulati
Women M
Death 11% 12
Death/MI/CVA 26% 22
Subsequent revascularization 35% 32
CHF 20% 16
*Adjusted for randomized treatment strategies (revascularization vs.
strata (PCI vs. CABG), age at entry, race ethnicity, United States versus
duration of DM, taking insulin at baseline, smoking status, disease myocardi
CI  confidence interval; CVA  cerebrovascular accident; HR  hazard rutcomes, although women were more likely than men to
ave CHF in follow-up. After adjustment for difference in
aseline variables, the hazard of death or death/MI/stroke
or women versus men was similar, as were the adjusted
ates of subsequent revascularization and CHF.
Angina, DASI, and self-rated health at baseline and at
ach annual visit are depicted in Figures 2, 3, and 4. A larger
ercentage of women than men reported angina in follow-
p. Women had lower reported scores for DASI and
elf-Rated Health. Even after adjusting for baseline status
nd other confounding variables, women were more likely
han men to report angina (adjusted OR: 1.51; 99% CI:
.21 to 1.89, p  0.0001), and women had significantly
ower DASI scores than men (adjusted beta coefficient:
1.58, 99% CI: 2.84 to 0.32, p  0.01). After adjust-
ent, self-rated health was not significantly different be-
ween women and men (adjusted beta coefficient: 0.32, 99%
I: 2.4 to 1.7, p  0.7).
ear
5-Yr
n
231) p Value
Women
(n  318)
Men
(n  759) p Value
0.09 90% 87% 0.15
0.07 41% 36% 0.16
0.21 89% 91% 0.21
0.01 27% 15% 0.01
0.01 77% 60% 0.01
0.55 94% 95% 0.74
0.81 95% 94% 0.57
0.38 64% 68% 0.16
0.28 42% 45% 0.30
0.20 9% 9% 0.71
15) (n  25) (n  68)
0.34 80% 87% 0.42
nt Rate
Adjusted* HR
Women vs. Men
p Value HR (99% CI) p Value
0.45 0.91 (0.63–1.32) 0.53
0.12 1.11 (0.85–1.44) 0.34
0.24 1.04 (0.82–1.31) 0.69
0.01 1.19 (0.87–1.63) 0.15
l therapy, and insulin provision vs. insulin sensitization), pre-specified
ountries, baseline characteristics including: MI, hypertension, angina,w-Up Y
4-Yr
Me
n  1,
85%
37%
90%
16%
57%
95%
94%
73%
49%
9%
(n  1
82%en
ve Eve
en
%
%
%
%
medica
other cal region, totally occluded region, and abnormal LVEF (50%).
atio; other abbreviations as in Tables 1, 2, and 3.
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In the current study, we analyzed the clinical presentation
and outcome of women and men enrolled in the BARI 2D
trial. The protocol-mandated trial design resulted in similar
management of women and men, including recommenda-
tions with regard to lifestyle changes, medical therapies, and
revascularization. When considering revascularization op-
tions, doctors advised a similar approach for women and
men, with comparable rates of PCI versus CABG after
adjusting for differences in baseline angiographic data and
other clinical variables. There were no sex differences in
procedural success for PCI, including the number of in-
tended and revascularized lesions and residual MJI. Women
undergoing CABG received fewer bypass grafts than men.
This was probably related to the less extensive and severe
disease reported at baseline in women; after adjusting for
baseline variables and extent of disease, this difference was
borderline significant. Despite this, success of revasculariza-
Figure 1 5-Year Cumulative Event Rates in Women and Men
The 5-year cumulative rate of death (A); and the combined endpoints of death, mtion, defined by residual MJI, was similar for women andmen after CABG. Women were more likely than men to be
prescribed non-sublingual nitrates and diuretics. Otherwise,
therapies for treatment of CAD were similar by sex. As one
might expect, given the very similar and intensive manage-
ment of CAD and DM in our patients, clinical outcomes
were equivalent between women and men, including mor-
tality and the combined endpoints of death, MI, and CVA
at 5 years of follow-up. This implies that the difference in
outcome between women and men reported in prior studies
might have been partly a result of sex-based differences in
management.
Despite the similarities in management, women re-
mained more symptomatic then men with more angina and
poorer functional status as assessed with the DASI question-
naire. These differences were noted even after adjusting for
other confounding variables. However, women and men had
equal adjusted scores for Self-Rated Health in follow-up. Our
study supports earlier reports that have demonstrated poorer
ial infarction, and cerebrovascular accident (B) in women and men.yocardQOL (16,23–26) and more angina (5,11,12,16,23,27) in
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nlike prior studies, the BARI 2D protocol allowed us to
nalyze symptoms between women and men who received
ntensive and highly regulated therapies for management
f CAD and DM; the extent of regulation and treatment
hat study participants received in BARI 2D is not often
chieved in the “real world.” It is interesting to note that,
ven though a similar percentage of women and men were
reated with statin therapy, women were less likely than
en to achieve the guideline-recommended target goal
or LDL 100 mg/dl. Although this finding is poten-
ially interesting, it is unlikely that this would explain the
oorer functional status or higher rates of angina in
omen.
Physical functioning is a complex variable that is influ-
nced by multiple co-existing conditions, including baseline
unctional status, the severity of the heart disease of a
atient, the presence of other comorbid illnesses (including
iastolic dysfunction, underlying lung disease, obesity, de-
enerative joint diseases, or prior CVA), and psychosocial
arriers. In the current analysis, we attempted to examine
OL by DASI scores, after adjusting for other variables
hat might have impacted on physical functioning; however,
t is possible that certain “unmeasured” variables (degener-
tive joint disease, lung disease, depression, and social
upport) might have contributed to a poorer functional
tatus in the women studied when compared with men.
Physical functioning is also affected by psychosocial
Figure 2 Angina Prevalence in Women and Men
Prevalence of angina in women and men at each yearly follow-up visit.actors, including depression, anxiety, and social support l28). Women with CAD experience more depression than
en and have less social support (16,23). In a large
rospective study of women and men with CAD (16),
unctional status was found to be significantly lower in
omen than men. In this study (16), women had higher
ates of depression and less social support; these variables
ere shown to have a negative impact on functional status.
hese data suggest that inadequate social support and
epression might adversely affect functional status, and
herefore, acquisition of a broader psycho-social history
ight be necessary when evaluating patients with CAD. It
s possible that a more aggressive approach to the assess-
ent and management of physical and psychosocial barriers
n patients with CAD (including referral to structured
ardiac rehabilitation programs, depression screening and
reatment, and programs designed to aid in social support)
ight contribute to an improvement in functional status in
omen.
The degree to which a patient might experience angina is
ependent on multiple conditions, including the severity of
therosclerotic CAD (or residual myocardium in jeopardy),
yocardial oxygen demand, the presence of microvascular
isease, the use of anti-anginal medications, the degree of
aseline angina, and patient perception of pain; all of these
actors might contribute to symptom presentation to a
ifferent degree in women and men. Our multivariate
nalysis adjusted for differences in baseline symptoms,
linical data, angiographic variables, and choice of revascu-
arization. Yet, women still had more angina than men. In
1774 Tamis-Holland et al. JACC Vol. 61, No. 17, 2013
Outcomes in Women and Men Enrolled in the BARI 2D Trial April 30, 2013:1767–76follow-up, there seemed to be comparable cardiovascular
disease-focused management of enrolled women and men,
including the approach to revascularization (for those pa-
tients randomized to revascularization), procedural success
after revascularization, and medical therapies used for the
treatment of angina. In fact, women were actually prescribed
anti-anginal medications more often than men. There-
fore, the differences we reported in rates of angina in
women and men were unlikely to be a result of differences
in therapies administered. It is not clear whether the
higher prevalence of angina in women reflects true
ischemia related to microvascular disease or a lowered
symptom threshold in women.
It is interesting to note that, at baseline, women had more
significant angina than men, despite the less extensive
disease noted on coronary angiography. This has been reported
in prior studies (1). Endothelial dysfunction or microvascu-
lar disease is a syndrome characterized by abnormalities in
vascular homeostasis and vasomotor tone, resulting in
ischemic-like symptoms and increased risk for cardiovascu-
Figure 3 Duke Activity Status Index in Women and Men
Scores recorded for the Duke Activity Status Index (DASI) in women and men
at each yearly follow-up visit.lar events. Syndrome X, which is defined as typical angina inthe setting of normal coronary angiograms, has been attrib-
uted in part to endothelial dysfunction (29) and is more
common in women (30).
Some studies have demonstrated sex differences in so-
matic pain perception and pain thresholds, with a lower pain
threshold in women and a lower tolerance for pain (31)
compared with men. However, other reports have suggested
that, among patients with physical conditions, women are
less likely to report symptoms than men (32). In our study,
although functional status was poorer and angina was more
frequent in women than men, women and men had com-
parable scores for self-rated health. If “perception of symp-
toms” related to health status was the reason for the lower
functional scores in women and the higher rates of angina,
one would expect that self-rated health would also be lower
in women than men. Yet, this was not noted. This implies
that the “perception of symptoms” of a woman related to
health status were less likely to be responsible for the
differences we noted in our study.
Figure 4 Self-Rated Health in Women and Men
Scores recorded for Self-Rated Health in women and men at each yearly
follow-up visit.
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cific population of patients with type 2 DM and stable
CAD amenable to revascularization. Because the BARI
2D trial only enrolled patients with stabilized CAD and
symptoms appropriate for treatment with either medical
therapy or revascularization, it is possible that we ex-
cluded patients with more extensive disease or more
severe symptoms requiring earlier intervention where
more pronounced sex differences might be observed.
Social support and depression were not routinely mea-
sured in our patients; therefore the degree to which these
variables impacted the differences in QOL and symptom-
atic angina could not be assessed. Finally, although
angina was routinely assessed at each visit, a standardized
questionnaire such as the Seattle Angina Questionnaire
was not administered.
Conclusions
Women and men with type 2 DM and CAD enrolled in
the BARI 2D trial received very similar management
strategies and had a similar incidence of cardiovascular
events over the 5-year period of follow-up. Despite these
similarities, women remained more symptomatic than
men, with more angina and persistence of lower func-
tional status even after adjustment for baseline variables
and therapies administered. Our findings offer important
insight into the clinical care of patients with DM and
stable CAD. In women with established CAD, consid-
eration should be given to more aggressive therapies
aimed at treatment of angina and individually prescribed
physical activity programs aimed at improvement in
functional capacity.
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